| Aug 7 |
Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference
|
| Aug 6 |
Compass Therapeutics Completes Patient Enrollment in COMPANION-002, a Randomized Study of CTX-009 in Combination with Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract Cancer
|
| Jul 12 |
Here's Why We're Not Too Worried About Compass Therapeutics' (NASDAQ:CMPX) Cash Burn Situation
|
| Jun 20 |
Compass Therapeutics: Pointing Right At Some Tough Cancers
|
| May 30 |
Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference
|
| May 28 |
Compass Therapeutics names Thomas Schuetz as CEO
|
| May 28 |
Compass Therapeutics Announces CEO Transition
|
| May 23 |
Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual ...
|
